Atlas Trials

Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Clinical trial NCT06690840 · RECRUITING

Trial details

NCT number
NCT06690840
Sponsor
European Institute of Oncology
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2025-03-06
Primary completion
2026-12-15
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.